Israel’s leading health tech investment firm aMoon announced on Monday that it is launching a new early-stage accelerator program in collaboration with Swiss biotech giant Roche.
The program aims to tap into innovative diagnostic technologies from the Israeli health tech ecosystem that address global healthcare challenges, aMoon said. The accelerator, called “StarFinder Lab,” will focus on identifying and cultivating “disruptive AI-driven data as well as digital healthcare solutions from the agile and highly skilled Israeli health tech ecosystem,” according to the announcement.
StarFinder Lab will provide funding, mentoring and strategic support to newly-formed or existing ventures picked for the program. Entrepreneurial teams will have access to global expertise from Roche and aMoon to build and tailor technologies for product-market fit.
Applications for the program will open in October 2020.
Dr. Yair Schindel, co-founder and managing partner at aMoon, said that “as a world-renowned digital innovation hub, Israel has robust entrepreneurial resources that can provide solutions to major challenges faced by the healthcare industry.”
As part of aMoon’s vision, he said, the firm looks to serve as a “partner to promising entrepreneurs with transformative technologies.”
“This partnership with Roche, a global leader in pharmaceuticals, diagnostics and digital health, has the potential to be a real game-changer for early-stage companies from across the healthcare industry, allowing them to move faster and with greater success,” Dr. Schindler said.
Michele Pedrocchi, head of global strategy and business development at Roche Diagnostics said the program “will allow us to build exceptional relationships with Israel’s brightest entrepreneurs, as well as take an active and strategic role in building disruptive startups…”
The Roche and aMoon program “offers a unique strategic partnership model from concept to global market,” said Roche Israel CEO Avi Danziger.
The accelerator’s emphasis “is on the best of the best talents who can deliver impactful solutions for defined global challenges in healthcare,” he went on.
aMoon was co-founded by Dr. Schindler and Marius Nacht, the billionaire co-founder of cybersecurity giant CheckPoint Software Technologies, and runs several health tech funds. The firm’s Velocity fund, focused on early-stage startups, recently led a funding round in Nectin Therapeutics, an Israeli developer of next-generation immuno-oncology biotherapies.
aMoon has also invested in MDClone, a Beersheba-based company providing healthcare data in real-time, and bio-medical tech company Theranica, the developer of a wearable device for treating migraines.
Roche is a major pharmaceutical and diagnostics multinational with headquarters in Basel.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
Ashdod Port Investing In Startups As Part Of Innovation Strategy
Facebook comments